Advancing Regenerative Medicine Translation in Minnesota
We equip investigators, innovators, and trainees with regulatory-aligned infrastructure, expertise, and nonhuman primate (NHP) resources to move promising regenerative therapies across critical translational milestones—from preclinical development to regulatory-ready studies. MN-BRIDGE is a Regenerative Medicine Minnesota–funded resource advancing late-stage preclinical regenerative medicine translation.
Closing the Translational Gap
Many regenerative medicine therapies stall in the gap between early discovery and clinical testing—the translational “valley of death.” MN-BRIDGE exists to close this gap by reducing technical, regulatory, and immunological risk through integrated, investigator-ready translational infrastructure. Through standardized workflows, high-quality biological resources, and hands-on training embedded within active research programs, we help generate decision-enabling data that supports confident advancement toward the clinic.
Whether you are launching a new project, advancing a regenerative therapy toward IND-enabling studies, or building translational expertise, MN-BRIDGE meets you where you are and helps move your work forward with confidence.
